CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
20% Intralipiddrug
Likely dose
20% Intralipid lipid infusionAI-extracted
Key inclusion· 1
  • Healthy subjects without diabetes or glucose intolerance
Key exclusion· 5
  • Diabetes or impaired glucose tolerance
  • Peripheral vascular disease
  • Pulmonary disease
  • Clinically significant hepatic or renal disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00330967
NCT00330967N/ACompleted

Mechanisms of Insulin Resistance in Humans

US Department of Veterans Affairs·observational·Posted May 29, 2006·Updated Apr 3, 2015

In Brief

An observational study evaluating 20% Intralipid for Inflammation and Insulin Resistance. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The Objectives of the study are to: (1)compare the inflammatory response and insulin resistance in skeletal muscles during a systemic infusion of lipid with that during a local infusion of lipid into the femoral artery. which would cause minimal or no systemic hyperlipidemia but local plasma free fatty acid (FFA) concentrations similar to those during the systemic lipid infusion, and (2) determine the inflammatory response and insulin resistance in skeletal muscle during an infusion of lipid into the femoral artery as described above after NF-KB inhibition by high dose salicylate treatment in humans.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 29, 2006
Enrollment StartApr 1, 2006
Primary CompletionJan 1, 2012
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 20.1 years ago

Interventions

20% Intralipiddrug

lipid infusion